4th HEPATITIS C
TECHNICAL ADVISORY
GROUP
TAG Meeting

HCV REINFECTION RATES AFTER TREATMENT IN PEOPLE WHO INJECT DRUGS OF A PROSPECTIVE COHORT IN TBILISI, GEORGIA

Tamar Kikvidze


Médecins du Monde/Doctors of the World



Background

- People who inject drugs (PWID) account for about 10% of the 71 million chronic HCV cases worldwide
- Estimated 23% of new HCV infections occur among PWID
- Low Uptake of HCV treatment among PWID
 - ✓ Criminalization
 - ✓ Discrimination
 - ✓ Concernes about adharence to treatment and reinfection


Methods – Experimental Scheme




Methods - Intervention

Counseling session provided by a peer including prevention


---- On demand peer support



Methods - Data collection



Results



Conclusions

- Low incidence of reinfection was observed in our PWID intervention cohort
- Further analysis is needed to understand how our intervention has influenced the behaviors of risk
- Concerns about reinfection should not be a reason for exclusion PWID from HCV treatment programs

<u>Limitations of the Study:</u>

- Control group numbers too small
- Too few reinfections
 - lack of power to compare the incidence with the control group
 - impossible to study the risk factors

Acknowledgements

- People who inject drugs (PWID) Community and especially the study participants
- Self –support organization "New Vector" and the peer-workers
- Clinic "Neolab" (George Kamkamidze, Maia Butsashvili)
- Médecins du Monde team in Tbilisi and Paris (Julie Bouscaillou, Niklas Luhmann, Aurelie Etienne, Diane le Pluart)
- French National Reference Center for Viral Hepatitis B, C and delta (Stéphane Chevaliez)

